Silexion Therapeutics 2024 net loss $16.5M, auditor flags going concern doubt

Silexion Therapeutics Corp

Net loss of $16.5M in 2024 vs $5.1M in 2023; operating expenses $12.6M.
Cash used in operations $8.4M; cash and equivalents $1.2M at Dec 31, 2024.
Auditor emphasizes substantial doubt about going concern due to recurring losses.
Total liabilities $6.9M exceed assets $2.9M; capital deficiency of $4.0M.
Financial statements retroactively adjusted for 1-for-15 reverse split effective July 28, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.